DexCom, Inc. — FY2022 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2022. Although the request identifies 2022 Q4, this filing reports full-year results; the supplied text does not provide a clear standalone Q4 financial summary. Amounts below are in U.S. dollars.
Business context
DexCom develops and sells continuous glucose monitoring (CGM) systems for diabetes management. Its G6 system remained a core product, and the FDA authorized the next-generation G7 in December 2022 for people with diabetes ages two and older. Revenue is generated primarily from disposable sensors, with sales through distributors and direct channels.
Financial performance and liquidity
| Metric | FY2022 | FY2021 | Change |
|---|---|---|---|
| Revenue | $2.910 billion | $2.449 billion | +19% |
| Gross profit / margin | $1.883 billion / 64.7% | $1.681 billion / 68.6% | Profit +12%; margin down 3.9 percentage points |
| Operating income / margin | $391.2 million / approximately 13% | $265.8 million / approximately 11% | +47% |
| Net income | $341.2 million | $216.9 million | +57% |
| Diluted earnings per share | $0.82 | $0.53 | +55% |
| Cash from operations | $669.5 million | $442.5 million | +51% |
| Capital expenditures | $364.8 million | $389.2 million | Down $24.4 million |
Revenue growth was driven mainly by higher disposable-sensor sales and a growing worldwide customer base. Sensor and other revenue represented 87% of FY2022 revenue, versus 84% in FY2021; reusable hardware accounted for the remainder. Gross margin declined due to price, product and channel mix, and foreign-currency effects. International revenue rose to 26% of total from 24%; distributor-channel revenue increased to 85% from 83%.
At year-end, cash, cash equivalents and short-term marketable securities totaled $2.46 billion, including $642.3 million of cash and cash equivalents and $1.81 billion of short-term marketable securities. Working-capital and quick ratios were 1.99 and 1.72, respectively. The company reported $1.970 billion of convertible notes on its balance sheet, with $1.982 billion aggregate principal outstanding: $774.8 million of 0.75% notes due December 2023 and $1.2075 billion of 0.25% notes due November 2025. The 2023 notes were classified partly as current liabilities. The $200 million revolving facility had no borrowings and $192.7 million available after letters of credit; DexCom reported compliance with its covenants. Cash from operations less capital expenditures was approximately $305 million, calculated from the reported figures.
Material changes and unusual items
- SG&A increased 24% to $1.000 billion, including higher compensation and marketing costs, $21.5 million in litigation expense, and a $23.0 million impairment charge related to a vacated San Diego building made available for sublease.
- R&D decreased 6% to $484.2 million, primarily from lower external development, equipment validation and clinical-trial costs, partly offset by higher compensation expense.
- FY2021 included an $87.1 million Verily collaboration R&D charge for a regulatory milestone. In 2022, DexCom issued approximately 2.9 million shares for that milestone and capitalized $152.4 million of Verily sales-based milestone value as an intangible asset after determining achievement was probable.
- DexCom repurchased $557.7 million of stock in 2022 under an accelerated share repurchase arrangement. Approximately $142.3 million remained under its $700 million authorization at year-end.
- Cash, cash equivalents and short-term marketable securities decreased by $275 million year over year. Investing cash outflow was $521.5 million and financing cash outflow was $552.5 million, including the stock repurchase.
- The filing reflects retrospective adoption of convertible-debt accounting guidance and a four-for-one stock split; comparative figures and per-share amounts were adjusted.
Outlook, management commentary and key risks
Management expects existing cash, short-term investments, operating cash generation and available credit to fund operations and anticipated liquidity needs for at least 12 months. It anticipates significant capital spending in the near term for the Malaysia manufacturing facility and capacity expansion in Mesa, Arizona. The Malaysia facility was expected to begin operations in 2023. The filing provides no specific 2023 revenue, earnings or margin guidance.
Management identifies demand growth, broader CGM adoption, reimbursement developments, digital-health demand, product innovation and the ability to scale manufacturing as important business trends. It also notes seasonal sales patterns, typically with lower first-quarter sales following fourth-quarter purchasing, related in part to insurance deductible resets.
- Reimbursement and pricing: Payor cost controls, restrictive coverage criteria and pricing pressure could constrain access, sales or margins. A proposed Medicare coverage expansion was not yet final in the filing.
- Manufacturing and suppliers: Capacity ramp-up, quality control, construction execution and single-source components could disrupt supply or raise costs. Management reported supply-chain constraints and possible gross-margin effects.
- Competition and product adoption: DexCom faces established CGM competitors, particularly Abbott, and must sustain product performance, innovation, reimbursement and market acceptance.
- Regulatory, product and legal exposure: Medical-device requirements, product quality or liability claims, and ongoing patent litigation with Abbott could result in expense, restrictions or disruption. The company said it did not believe other then-pending proceedings were expected to have a material adverse effect.
- Cybersecurity and privacy: Data-security incidents and evolving U.S. and foreign privacy rules could create operational, legal, reputational and compliance costs.
- Economic and currency risks: Inflation, labor and component costs, foreign exchange movements, interest rates and international conditions may affect demand, costs and reported results.
The independent auditor issued unqualified opinions on the financial statements and internal control over financial reporting. Pharmacy-rebate estimation was identified as a critical audit matter; management noted that a 1% change in its estimate of products subject to rebates would change revenue by approximately $19.1 million.
Important facts for investors to verify
- Progress of G7 commercialization, reimbursement coverage, customer adoption and any associated product or supply issues.
- Whether DexCom can restore gross-margin performance as pricing, product and channel mix evolve and foreign-exchange effects change.
- Manufacturing expansion and capacity execution in Malaysia and Mesa, including the effect of supply constraints and capital spending.
- Cash settlement, conversion or refinancing plans for the $774.8 million principal amount of notes due in December 2023, and the remaining 2025 notes.
- Developments in the Abbott patent proceedings and any material financial or operational consequences.
- Pharmacy-rebate estimates, customer/distributor concentration, and the accounting and potential dilution implications of Verily milestones.